NasdaqGS:REPLBiotechs
Will FDA Progress Change Replimune Group's (REPL) Position in the Advanced Melanoma Treatment Market?
Replimune Group, Inc. recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RP1 in combination with nivolumab, intended for advanced melanoma patients who have progressed on anti-PD-1 therapies, with a new PDUFA target date set for April 10, 2026.
This regulatory acceptance represents a major step for Replimune after the company addressed earlier FDA feedback, potentially opening the door to new treatment options for patients with limited...